New York, New York-- (Newsfile Corp. - March 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of BioAge Labs (NasdaqGS:BIOA) with a Market ...

SAN FRANCISCO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase 2 trial.

On or about September 2024, BioAge conducted its IPO, selling 12.65 million shares of stock for $18 per share. On December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. pursuant and/or traceable to the registration statement for BioAge's initial public offering ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

Class Action, Consumer Services, GlobeNewswire, Law & Legal Issues | NEW YORK, March 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law ...

BIOA Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 DeadlineSAN FRANCISCO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- B ...

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for ...

BioAge Labs (BIOA) has filed for an upsized 10,500,000 share IPO at $17-$19 per share. The company previously indicated a 7.5M share offering in the same price range.